Figure 2.
Efficacy endpoints: Overall survival and best overall responses. OS according to the cohort (A) and BOR (B). Of the 65 deaths, causes included disease progression (n = 36), graft-versus-host disease (n = 5), sepsis and/or septic shock (n = 3), pneumonia (n = 3), cardiac arrest (n = 2), multiple organ failure (n = 2), lung cancer (n = 1), Epstein-Barr virus-positive T-cell lymphoma with multiple organ failure (n = 1), adverse reaction to allo-HCT (n = 1), allo-HCT complicated by graft-versus-host disease (n = 1), heart failure (n = 1), post-transplant complications (n = 1), respiratory infection (n = 1), hemorrhagic cystitis (n = 1), acute hypoxemic respiratory failure secondary to pneumocystic pneumonia (n = 1), and unknown causes (n = 5).

Efficacy endpoints: Overall survival and best overall responses. OS according to the cohort (A) and BOR (B). Of the 65 deaths, causes included disease progression (n = 36), graft-versus-host disease (n = 5), sepsis and/or septic shock (n = 3), pneumonia (n = 3), cardiac arrest (n = 2), multiple organ failure (n = 2), lung cancer (n = 1), Epstein-Barr virus-positive T-cell lymphoma with multiple organ failure (n = 1), adverse reaction to allo-HCT (n = 1), allo-HCT complicated by graft-versus-host disease (n = 1), heart failure (n = 1), post-transplant complications (n = 1), respiratory infection (n = 1), hemorrhagic cystitis (n = 1), acute hypoxemic respiratory failure secondary to pneumocystic pneumonia (n = 1), and unknown causes (n = 5).

Close Modal

or Create an Account

Close Modal
Close Modal